+12.7%
SHEL vs MRNA
+161.9%
-149.2%
-18.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 6mo.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.8% | +5.4% | -4.5% | +0.9% |
| 7D | +4.1% | -1.1% | +5.2% | +4.1% |
| 30D | +8.4% | +126.1% | -117.7% | +8.4% |
| 3M | +13.7% | +190.0% | -176.3% | +16.3% |
| 6M | +12.7% | +157.2% | -144.5% | +16.1% |
| All | +12.7% | +161.9% | -149.2% | +16.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 6mo: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
6mo analysis · Full analysis span regression · 6 months rolling